摘要
目的观察扶正抗癌方对非小细胞肺癌化疗患者增效减毒作用。方法将182例非小细胞肺癌患者随机分为2组,对照组91例给予紫杉醇^+顺铂化疗方案,研究组91例在对照组治疗基础上给予扶正抗癌方口服,均治疗4个周期。观察2组治疗前后T淋巴细胞亚群、TGF-α、TGF-β_1、VEGF、KPS评分变化,统计2组近期疗效、生存率和不良反应发生率。结果研究组治疗后CD3^+、CD4^+、CD4^+/CD8^+、KPS评分、1年生存率、2年生存率与对照组相比较均显著升高(P均<0.05);TGF-α、TGF-β_1、VEGF水平和不良反应发生率与对照组比较均显著降低(P均<0.05)。结论扶正抗癌方联合化疗治疗非小细胞肺癌可改善免疫功能,降低不良反应发生率,提高近期疗效,具有临床推广价值。
Objective It is to observe the synergistic and att chemotherapy of non small cell lung cancer. Methods 182 cases enuated action of Fuzheng Kangai Prescription of non-small cell lung cancer patients （FZKAP） on domly divided into 2 groups, 91 cases in the control group were given paclitaxel ＋ cisplatin chemotherapy, 91 cases in the study group were treated with FZKAP orally on the basis of the control group were treated. All patients were treated for four cycles. The T lym- phocyte subsets, TGF-alpha, TGF-beta 1 , VEGF, KPS score in the 2 groups were observed before and after treatment, and the curative effect, survival rate and incidence of adverse reactions were compared between the 2 groups. Results After treat- ment, the levels of CD3＋ , CD4 ＋ , the value of CD4 ＋/CD8 ＋ , the KPS score, and the survival rate of 1 year, 2 years of the study group were increased significantly compared with the control group （ all P 〈 0.05 ） ; the levels of TGF-α, TGF-β1 , VEGF, and the occurrence rate of adverse reactions were decreased significantly compared with the control group （all P 〈 0. 05）. Conclusion FZKAP combined with chemotherapy in the treatment of non small cell lung cancer, can enhance the immunity function, reduce adverse reaction, improve curative effect, and it has clinical value of promotion.
出处
《现代中西医结合杂志》
CAS
2017年第27期2992-2995,共4页
Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词
非小细胞肺癌
化疗
扶正抗癌方
毒副反应
non small cell lung cancer
chemotherapy
Fuzheng Kangai Prescription
toxic and side effect
